Merck比收入估计数高,尽管收入略有下降,但2025年的前景展望有所提高。 Merck beats earnings estimates, raises 2025 outlook despite slightly lower revenue.

Merck & Co.报告第二季度收入强劲,经调整的EPS收入为2.13美元、粗略估计和收入158.1亿美元,略低于预测。 Merck & Co. reported strong second-quarter earnings with adjusted EPS of $2.13, beating estimates, and revenue of $15.81 billion, slightly below forecasts. 该公司将其2025年全年EPS指南提高到8.87至8.97美元,分析人员预计为9.01美元。 The company raised its 2025 full-year EPS guidance to $8.87–8.97, with analysts expecting $9.01. Merck公司保持稳固的财政状况,市场上限为198.88亿美元,P/E比率为12.27,股息收益率为4.1%。 Merck maintains a solid financial profile with a market cap of $198.88 billion, a 12.27 P/E ratio, and a 4.1% dividend yield. 机构投资者持有76.07%的股票,股票的贝特值为0.37。 Institutional investors hold 76.07% of shares, and the stock has a beta of 0.37. 该公司在药品、动物健康和消费者护理方面运作,具有一致的“稳住”评级和106.41美元的价格目标。 The company operates in pharmaceuticals, animal health, and consumer care, with a consensus "Hold" rating and a $106.41 price target.